Structures by: Bourne S. A.
Total: 172
None
C19H28N2O7S2,0.5(H2O1)
Journal of Pharmaceutical Sciences (2015) 104, 3418-3425
a=9.4990(13)Å b=10.5848(15)Å c=43.643(6)Å
α=90.00° β=90.00° γ=90.00°
2-methoxyestradiol chloroform solvate 1:2
C19H26O3,2(C1H1Cl3)
Journal of Pharmaceutical Sciences (2015) 104, 3418-3425
a=6.3150(2)Å b=9.3352(3)Å c=11.1622(5)Å
α=104.386(2)° β=95.464(2)° γ=107.774(2)°
2-methoxyestradiol
C19H26O3
Journal of Pharmaceutical Sciences (2015) 104, 3418-3425
a=6.2540(2)Å b=11.2919(3)Å c=11.5524(4)Å
α=90.00° β=97.3550(10)° γ=90.00°
4,4-isopropylidene bisphenol-3,4-xylenol
C23H26O3
CrystEngComm (2020)
a=6.4218(6)Å b=14.8289(14)Å c=20.2173(19)Å
α=90° β=96.132(2)° γ=90°
4,4-isopropylidene bisphenol-2,3-xylenol-3,5-xylenol
C92H104O12
CrystEngComm (2020)
a=6.3007(3)Å b=20.7627(11)Å c=29.9858(14)Å
α=90° β=95.787(2)° γ=90°
4,4-isopropylidene bisphenol-4,4'-(9-fluorenylidene) bisphenol-2,6-xylenol-3,5-xylenol
C88H78O9
CrystEngComm (2020)
a=21.0580(9)Å b=15.5380(6)Å c=21.2490(10)Å
α=90° β=98.4810(10)° γ=90°
C19H22.1N2O4.2SZn
C19H22.1N2O4.2SZn
New Journal of Chemistry (2019) 43, 36 14343
a=18.8659(13)Å b=13.3682(9)Å c=17.1126(12)Å
α=90° β=107.432(2)° γ=90°
C44H32Cu2N4O12
C44H32Cu2N4O12
New Journal of Chemistry (2019) 43, 36 14343
a=9.7035(7)Å b=18.8466(14)Å c=10.6948(8)Å
α=90° β=102.326(2)° γ=90°
1,4-bis(9-hydroxyfluoren-9-yl)benzene. 4-picoline and morpholine clathrate
C32H22O2,C6H7N,C4H9NO
New Journal of Chemistry (2011) 35, 7 1556
a=16.8977(2)Å b=13.9004(2)Å c=28.3312(4)Å
α=90.00° β=90.1030(10)° γ=90.00°
1,4-bis(9-hydroxyfluoren-9-yl)benzene. 3-picoline clathrate
C32H22O2,2(C6H7N)
New Journal of Chemistry (2011) 35, 7 1556
a=9.4854(2)Å b=13.3617(3)Å c=14.0639(4)Å
α=82.2870(10)° β=81.0670(10)° γ=72.2300(10)°
1,4-bis(9-hydroxyfluoren-9-yl)benzene. 2-picoline clathrate
C32H22O2,2(C6H7N)
New Journal of Chemistry (2011) 35, 7 1556
a=14.5758(4)Å b=15.5947(4)Å c=14.6354(4)Å
α=90.00° β=90.9070(10)° γ=90.00°
1,4-bis(9-hydroxyfluoren-9-yl)benzene. 4-picoline clathrate
C32H22O2,2(C6H7N)
New Journal of Chemistry (2011) 35, 7 1556
a=8.15290(10)Å b=8.48480(10)Å c=12.4124(3)Å
α=93.6150(10)° β=90.8030(10)° γ=103.7880(10)°
1,4-bis(9-hydroxyfluoren-9-yl)benzene. morpholine clathrate
C32H22O2,2(C4H9NO)
New Journal of Chemistry (2011) 35, 7 1556
a=8.9644(3)Å b=9.5296(3)Å c=10.7651(4)Å
α=101.6810(10)° β=91.685(2)° γ=114.011(2)°
1,4-bis(9-hydroxyfluoren-9-yl)benzene. pyridine clathrate
C32H22O2,2(C5H5N)
New Journal of Chemistry (2011) 35, 7 1556
a=8.8538(3)Å b=10.4545(4)Å c=17.0843(8)Å
α=90.00° β=97.838(2)° γ=90.00°
Heptakis(2,6-di-O-methyl)-beta-cyclodextrin.6,7,8,9,10,10 - hexachloro-1,5,5a,6,9,9a-hexahydro-6,9-methano-2,4,3-benzodioxathiepin 3-oxide
C56H98O35,C9H6Cl6O3S,1.04(H2O)
New Journal of Chemistry (2012) 36, 10 2007
a=26.907(4)Å b=29.784(4)Å c=20.352(3)Å
α=90.00° β=90.00° γ=90.00°
2(Ag4,4(C16H23ON2S))
2(Ag4,4(C16H23ON2S))
New Journal of Chemistry (2006) 30, 8 1155
a=17.805(4)Å b=21.759(4)Å c=36.438(7)Å
α=90.00° β=96.34(3)° γ=90.00°
4-(1-hydroxy-1,2-diphenylethyl)pyridium chloride
C19H18NO,Cl
New Journal of Chemistry (2010) 34, 3 405
a=6.3219(13)Å b=8.4477(17)Å c=15.349(3)Å
α=102.22(3)° β=92.54(3)° γ=106.21(3)°
4-(1-hydroxy-1,2-diphenylethyl)pyridine
C19H17NO
New Journal of Chemistry (2010) 34, 3 405
a=9.3446(19)Å b=10.612(2)Å c=15.267(3)Å
α=90.00° β=107.70(3)° γ=90.00°
C45H39La2N9O15
C45H39La2N9O15
RSC Advances (2020) 10, 6 3593-3605
a=18.0826(12)Å b=13.3216(9)Å c=21.9623(15)Å
α=90° β=90° γ=90°
Tetracarbonyl-bis(triphenylphosphine)-molybdenum
C40H30MoO4P2
CrystEngComm (2018) 20, 35 5137
a=9.4289(7)Å b=38.395(3)Å c=9.9447(7)Å
α=90° β=107.8760(10)° γ=90°
C16H18N3OP
C16H18N3OP
Chemical Communications (1999) 9 853
a=8.201(3)Å b=9.0538(16)Å c=20.266(2)Å
α=90.00° β=91.648(17)° γ=90.00°
C32H36N6O2P2
C32H36N6O2P2
Chemical Communications (1999) 9 853
a=13.959(3)Å b=13.773(2)Å c=16.077(4)Å
α=90.00° β=113.44(3)° γ=90.00°
[1,3-benzenedicarboxylate-1,2-bis(4-pyridyl)ethane-zinc(II)] benzene solvate
C35H31N2O4Zn
Chemical Communications (2001) 9 861
a=9.6724(10)Å b=20.217(2)Å c=14.9774(15)Å
α=90.00° β=93.545(2)° γ=90.00°
[1,3-benzenedicarboxylate-1,2-bis(4-pyridyl)ethane-zinc(II)] nitrobenzene solvate
C35H40N4O10Zn3
Chemical Communications (2001) 9 861
a=10.5457(15)Å b=18.400(3)Å c=15.209(2)Å
α=90.00° β=90.971(3)° γ=90.00°
[1,3-benzenedicarboxylate-1,2-bis(4-pyridyl)ethane-zinc(II)] toluene solvate
C34H32N2O4Zn
Chemical Communications (2001) 9 861
a=10.243(3)Å b=18.317(5)Å c=15.391(4)Å
α=90.00° β=91.116(5)° γ=90.00°
[1,3-benzenedicarboxylate-1,2-bis(4-pyridyl)ethane-zinc(II)] benzaldehyde solvate
C34H28N2O6Zn
Chemical Communications (2001) 9 861
a=10.437(2)Å b=18.516(4)Å c=15.190(3)Å
α=90.00° β=90.119(4)° γ=90.00°
[1,3-benzenedicarboxylate-1,2-bis(4-pyridyl)ethane-zinc(II)] 1,4-dioxane solvate
C30H36N2O9Zn
Chemical Communications (2001) 9 861
a=10.5454(13)Å b=20.202(2)Å c=14.2392(17)Å
α=90.00° β=96.781(2)° γ=90.00°
[1,3-benzenedicarboxylate-1,2-bis(4-pyridyl)ethane-zinc(II)] dichloromethane solvate
C10.5H9ClNO2Zn0.5
Chemical Communications (2001) 9 861
a=10.0200(10)Å b=15.1945(15)Å c=13.6885(13)Å
α=90.00° β=90.00° γ=90.00°
[1,3-benzenedicarboxylate-1,2-bis(4-pyridyl)ethane-zinc(II)] methanol solvate
C10.5H9.5NO2.5Zn0.5
Chemical Communications (2001) 9 861
a=9.676(3)Å b=15.470(5)Å c=13.547(5)Å
α=90.00° β=90.00° γ=90.00°
Heptakis(2,3,6-tri-O-methyl)-beta-cyclodextrin
C63H112O35
Chemical Communications (2004) 19 2216-2217
a=15.9509(1)Å b=16.5772(1)Å c=28.9413(2)Å
α=90.00° β=90.00° γ=90.00°
Heptakis(2,3,6-tri-O-methyl)-beta-cyclodextrin trihydrate
C63H112O35.3H2O
Chemical Communications (2004) 19 2216-2217
a=16.2051(1)Å b=16.2870(1)Å c=30.0989(3)Å
α=90.000° β=90.000° γ=90.000°
((2-pyridylmethyl)ammonium) (m-iodobenzoate)
C6H9N2,C7H4IO2
CrystEngComm (2008) 10, 12 1750
a=16.4778(7)Å b=6.0706(2)Å c=14.3327(5)Å
α=90° β=108.452(2)° γ=90°
(benzylammonium)(m-iodobenzoate)
C7H10N,C7H4IO2
CrystEngComm (2008) 10, 12 1750
a=14.689(3)Å b=10.544(2)Å c=8.6613(17)Å
α=90° β=91.03(3)° γ=90°
((3-pyridylmethyl)ammonium)(m-iodobenzoate)
C6H9N2,C7H4IO2
CrystEngComm (2008) 10, 12 1750
a=12.451(3)Å b=6.1494(12)Å c=17.582(4)Å
α=90° β=96.47(3)° γ=90°
(m-iodobenzoic)(((4-pyridylamethl)ammonium)(m-iodobenzoate)
C6H9N2,C7H5IO2,C7H4IO2
CrystEngComm (2008) 10, 12 1750
a=34.329(7)Å b=6.2971(13)Å c=21.548(4)Å
α=90° β=114.77(3)° γ=90°
((4-pyridylamethyl)ammonium)(m-iodobenzoate)
C6H9N2,C7H4IO2
CrystEngComm (2008) 10, 12 1750
a=6.56520(10)Å b=17.7228(4)Å c=11.8193(2)Å
α=90° β=91.0100(10)° γ=90°
1,4-bis(9-hydroxyfluoren-9-yl)benzene. aniline clathrate
C32H22O2.C6H7N
CrystEngComm (2004) 6, 12 54
a=10.375(2)Å b=12.404(3)Å c=22.100(4)Å
α=90° β=90.46(3)° γ=90°
None
C32H22O2.3(C7H9N)
CrystEngComm (2004) 6, 12 54
a=22.524(3)Å b=22.524(3)Å c=16.721(3)Å
α=90.00° β=90.00° γ=90.00°
((R)-1-phenylethylammonium) 2-naphthalenecarboxylate
C8H12N,C11H7O2
CrystEngComm (2008) 10, 11 1605
a=6.3682(13)Å b=14.511(3)Å c=17.457(4)Å
α=90° β=90° γ=90°
((S)-1-phenylethylammonium) 2-naphthalenecarboxylate
C8H12N,C11H7O2
CrystEngComm (2008) 10, 11 1605
a=6.3709(13)Å b=14.513(3)Å c=17.445(4)Å
α=90° β=90° γ=90°
Bis((R)-1-phenylethylammonium) naphthalene-2,6-dicarboxylate
C12H6O4,2(C8H12N)
CrystEngComm (2008) 10, 11 1605
a=9.6633(4)Å b=6.3731(3)Å c=19.7210(7)Å
α=90° β=96.041(2)° γ=90°
Bis((S)1-phenylethylammonium) 2,6-naphthalenedicarboxylate
C12H6O4,2(C8H12N)
CrystEngComm (2008) 10, 11 1605
a=9.6656(12)Å b=6.3707(9)Å c=19.708(2)Å
α=90° β=96.025(7)° γ=90°
Bis((RS)-1-phenylethylammonium) 26-naphthalenedicarboxylate
C8H12N,C11H7O2
CrystEngComm (2008) 10, 11 1605
a=6.1388(5)Å b=10.6194(5)Å c=12.8861(9)Å
α=105.398(4)° β=101.879(3)° γ=98.163(5)°
Bis((RS)-1-phenylethylammonium) naphthalenedicarboxylate
C12H6O4,2(C8H12N)
CrystEngComm (2008) 10, 11 1605
a=6.1211(5)Å b=9.6478(8)Å c=10.5813(11)Å
α=94.483(4)° β=98.503(4)° γ=103.126(5)°
N,N,4-tris(pyridin-2-ylmethyl)aniline
C24H22N4
CrystEngComm (2007) 9, 11 997
a=9.4861(19)Å b=6.0392(12)Å c=32.990(7)Å
α=90.00° β=95.82(3)° γ=90.00°
None
[Mn(tpma)Cl2]
CrystEngComm (2007) 9, 11 997
a=8.7284(2)Å b=17.3023(3)Å c=15.7446(4)Å
α=90.00° β=102.2360(10)° γ=90.00°
C24H22Cl2.03CuN4O2.79
C24H22Cl2.03CuN4O2.79
CrystEngComm (2007) 9, 11 997
a=9.4866(3)Å b=12.7984(5)Å c=13.0868(5)Å
α=98.379(2)° β=104.084(2)° γ=91.693(2)°
[Co(tpma)(NO3)2]
[Co(tpma)(NO3)2]
CrystEngComm (2007) 9, 11 997
a=9.3562(2)Å b=10.2179(2)Å c=13.8837(4)Å
α=101.0790(10)° β=96.1500(10)° γ=110.0150(10)°
[Cu(tpmaH)(NO32](NO3)
[Cu(tpmaH)(NO32](NO3)
CrystEngComm (2007) 9, 11 997
a=8.0308(16)Å b=8.6296(17)Å c=20.091(4)Å
α=93.94(3)° β=92.29(3)° γ=116.16(3)°
C26H30CoN4O6S
C26H30CoN4O6S
CrystEngComm (2007) 9, 11 997
a=10.6604(2)Å b=10.7821(2)Å c=11.5302(2)Å
α=80.9020(10)° β=84.2830(10)° γ=79.0480(10)°
C24H29CuN4O8.25S1.25
C24H29CuN4O8.25S1.25
CrystEngComm (2007) 9, 11 997
a=9.4677(2)Å b=10.1790(2)Å c=16.2431(4)Å
α=79.7890(10)° β=75.9070(10)° γ=71.3780(10)°
C24H22Cl4Cu2N4O2
C24H22Cl4Cu2N4O2
CrystEngComm (2007) 9, 11 997
a=8.46750(10)Å b=12.8704(2)Å c=24.3518(4)Å
α=90.00° β=90.00° γ=90.00°
C24.20H22Cl4Cu2N4O0.20
C24.20H22Cl4Cu2N4O0.20
CrystEngComm (2007) 9, 11 997
a=8.5212(2)Å b=12.8596(3)Å c=24.1208(5)Å
α=90.00° β=90.00° γ=90.00°
Nevirapine-glutaric acid 1:1 co-crystal
C15H14N4O,C5H8O4
CrystEngComm (2012) 14, 7 2541
a=7.363(4)Å b=12.292(6)Å c=12.305(6)Å
α=118.571(8)° β=90.144(9)° γ=98.023(8)°
Nevirapine-maleic acid 1:1 co-crystal
C15H14N4O,C4H4O4
CrystEngComm (2012) 14, 7 2541
a=7.4001(5)Å b=10.4599(7)Å c=23.2561(16)Å
α=90.00° β=98.9680(10)° γ=90.00°
Nevirapine-rac-tartaric acid 1:1 co-crystal
C15H14N4O,C4H6O6
CrystEngComm (2012) 14, 7 2541
a=9.877(2)Å b=19.286(4)Å c=9.6971(19)Å
α=90.00° β=90.66(3)° γ=90.00°
Nevirapine-saccharin 2:1 cocrystal
2(C15H14N4O),C7H5NO3S
CrystEngComm (2012) 14, 7 2541
a=9.5649(5)Å b=13.8069(7)Å c=13.8726(7)Å
α=64.090(3)° β=79.292(2)° γ=82.686(2)°
Nevirapine-salicylic acid 2:1 co-crystal
2(C15H14N4O),C7H6O3
CrystEngComm (2012) 14, 7 2541
a=11.1549(14)Å b=12.6194(15)Å c=13.4644(16)Å
α=113.374(2)° β=99.133(2)° γ=107.324(2)°
Cis-Bis((mu2-3,3,3',3'-tetraethyl-1,1'- isophthaloylbis(thioureato))di iodoplatinum(IV))
C36H48I4N8O4Pt2S4
Dalton transactions (Cambridge, England : 2003) (2005) 17 2916-2924
a=10.087(2)Å b=10.498(2)Å c=11.975(2)Å
α=84.50(3)° β=87.24(3)° γ=80.80(3)°
Cis-bis((mu2-3,3,3',3'-tetraethyl-1,1'- isophthaloylbis(thioureato))di chloroplatinum(IV))
C36H48Cl4N8O4Pt2S4
Dalton transactions (Cambridge, England : 2003) (2005) 17 2916-2924
a=9.2600(19)Å b=17.863(4)Å c=14.504(3)Å
α=90.00° β=107.08(3)° γ=90.00°
Cis-Bis(N,N-diethyl-N'-benzoylthioureato)diiodoplatinum(IV)
C24H30I2N4O2PtS2
Dalton transactions (Cambridge, England : 2003) (2005) 12 2162-2172
a=8.8108(18)Å b=10.920(2)Å c=16.228(3)Å
α=74.23(3)° β=78.50(3)° γ=75.76(3)°
Cis-Bis(N,N-diethyl-N'-benzoylthioureato)platinum(IV)
C24H30Br2N4O2PtS2
Dalton transactions (Cambridge, England : 2003) (2005) 12 2162-2172
a=26.321(5)Å b=15.743(3)Å c=18.693(4)Å
α=90.00° β=130.64(3)° γ=90.00°
Trans-Bis(N-benzoyl-N'-propylthiourea-kS)diiodoplatinum(ii) di-iodine
C22H28I2N4O2PtS2,I2
Dalton transactions (Cambridge, England : 2003) (2005) 12 2162-2172
a=8.5127(17)Å b=9.4001(19)Å c=10.064(2)Å
α=77.00(3)° β=80.70(3)° γ=86.19(3)°
Trans-Bis(N-benzoyl-N'-propylthiourea- kS)tetrabromoplatinum(IV)
C22H28Br4N4O2PtS2,C7H8
Dalton transactions (Cambridge, England : 2003) (2005) 12 2162-2172
a=13.568(4)Å b=13.739(4)Å c=18.962(6)Å
α=90.00° β=103.338(5)° γ=90.00°
9,9'-(ethyne-1,2-diyl)-bis(fluoren-9-ol)
C28H18O2
CrystEngComm (2017)
a=18.455(4)Å b=14.363(3)Å c=15.938(3)Å
α=90.00° β=113.45(3)° γ=90.00°
9,9'-(ethyne-1,2-diyl)-bis(fluoren-9-ol) bis (3-pentanol) Clathrate
C28H18O2,C5H12O1,C5H12O1,C28H18O2,C5H12O1,C5H12O1,C28H18O2,C5H12O1,C5H12O1
CrystEngComm (2017)
a=9.6915(19)Å b=15.380(3)Å c=16.438(3)Å
α=91.21(3)° β=98.29(3)° γ=91.87(3)°
9,9'-(ethyne-1,2-diyl)-bis(fluoren-9-ol) bis (1-butanol) Clathrate
C28H18O2,C5H12O1,C5H12O1
CrystEngComm (2017)
a=8.8074(18)Å b=13.145(3)Å c=14.259(3)Å
α=75.84(3)° β=73.56(3)° γ=78.70(3)°
9,9'-(ethyne-1,2-diyl)-bis(fluoren-9-ol) bis (3-methyl2-butanol) Clathrate
C28H18O2,C5H12O1,C5H12O1
CrystEngComm (2017)
a=9.869(2)Å b=13.153(3)Å c=14.186(3)Å
α=63.18(3)° β=86.27(3)° γ=83.31(3)°
4,4-isopropylidene bisphenol-2,3-xylenol-2,6-xylenol
C46H52O6
CrystEngComm (2020)
a=30.650(2)Å b=6.3048(5)Å c=39.852(3)Å
α=90° β=91.359(2)° γ=90°
4-(1-hydroxy-1,2-diphenylethyl)pyridium nitrate
C19H18NO,NO3
New Journal of Chemistry (2010) 34, 3 405
a=6.3168(13)Å b=8.1971(16)Å c=16.497(3)Å
α=100.78(3)° β=91.20(3)° γ=100.44(3)°
Cis-bis((mu2-3,3,3',3'-tetraethyl-1,1'- isophthaloylbis(thioureato))di bromoplatinum(IV))
C36H48Br4N8O4Pt2S4
Dalton transactions (Cambridge, England : 2003) (2005) 17 2916-2924
a=9.2877(11)Å b=18.736(2)Å c=13.8036(16)Å
α=90.00° β=103.137(2)° γ=90.00°
9,9'-(ethyne-1,2-diyl)-bis(fluoren-9-ol) bis (2-pentanol) Clathrate
C28H18O2,C5H12O1,C5H12O1
CrystEngComm (2017)
a=8.5130(17)Å b=9.5480(19)Å c=12.017(2)Å
α=101.52(3)° β=103.71(3)° γ=114.49(3)°
9,9'-(ethyne-1,2-diyl)-bis(fluoren-9-ol)
C28H18O2
CrystEngComm (2017)
a=9.7243(19)Å b=10.424(2)Å c=14.814(3)Å
α=94.05(3)° β=102.03(3)° γ=93.31(3)°
9,9?-(ethyne-1,2-diyl)-bis(fluoren-9-ol) (2-methyl-2-propanol) (2-propanol) Clathrate
C28H18O2,C4H10O1,C3H8O1
CrystEngComm (2017)
a=10.328(2)Å b=11.176(2)Å c=18.112(4)Å
α=75.76(3)° β=79.16(3)° γ=88.31(3)°
Tri 9,9?-(ethyne-1,2-diyl)-bis(fluoren-9-ol) tetra (2-propanol) Clathrate
3(C28H18O2),4(C3H8O1)
CrystEngComm (2017)
a=10.150(2)Å b=10.397(2)Å c=18.780(4)Å
α=104.29(3)° β=94.58(3)° γ=96.70(3)°
Bi 9,9?-(ethyne-1,2-diyl)-bis(fluoren-9-ol) bis (2-propanol) (chloroform) Clathrate
2(C28H18O2),3(C3H8O1),C1Cl3H1
CrystEngComm (2017)
a=9.6930(19)Å b=14.066(3)Å c=21.052(4)Å
α=83.94(3)° β=82.70(3)° γ=89.93(3)°
9,9?-(ethyne-1,2-diyl)-bis(fluoren-9-ol) tetra (2-methyl-2-propanoll) Clathrate
C28H18O2,4(C4H10O1)
CrystEngComm (2017)
a=9.4041(19)Å b=9.4706(19)Å c=12.423(3)Å
α=111.38(3)° β=96.88(3)° γ=95.54(3)°
9,9?-(ethyne-1,2-diyl)-bis(fluoren-9-ol) bis (tert-butanol) Clathrate
C28H18O2,2(C4H10O1)
CrystEngComm (2017)
a=8.5974(17)Å b=9.1212(18)Å c=11.602(2)Å
α=92.96(3)° β=102.02(3)° γ=117.04(3)°
Tri 9,9?-(ethyne-1,2-diyl)-bis(fluoren-9-ol) tetra (2-propanol) Clathrate
3(C28H18O2),4(C3H8O1)
CrystEngComm (2017)
a=10.314(2)Å b=18.768(4)Å c=20.269(4)Å
α=83.06(3)° β=81.59(3)° γ=82.49(3)°
Clevudine (Form 2)
C10H13FN2O5
CrystEngComm (2016) 18, 42 8172
a=8.9716(9)Å b=5.3099(5)Å c=11.8624(11)Å
α=90° β=105.980(2)° γ=90°
Clevudine (Form 1)
C10H13FN2O5
CrystEngComm (2016) 18, 42 8172
a=10.3584(10)Å b=10.8540(10)Å c=10.4469(10)Å
α=90° β=108.403(2)° γ=90°
Clevudine (Form 3)
C10H13FN2O5
CrystEngComm (2016) 18, 42 8172
a=10.4391(13)Å b=16.017(2)Å c=13.8687(18)Å
α=90° β=101.604(2)° γ=90°
Fac-tris-(N-(pyrolidine)-N'-(2,2- dimethylpropanoyl)thioureato))rhodium(iii)
C30H51N6O3Rh1S3.(CHCl3)
Dalton Trans. (2003) 10 1952-1960
a=10.697(4)Å b=13.454(6)Å c=14.432(6)Å
α=84.77(3)° β=89.81(3)° γ=78.88(3)°
Bis-(N-piperidyl-N'-(2,2- dimethylpropanoyl)thioureato)platinum(ii)
C22H38N4O2PtS2
Dalton Trans. (2003) 10 1952-1960
a=9.951(2)Å b=15.235(3)Å c=18.358(4)Å
α=90.00° β=105.20(3)° γ=90.00°
Catena-(mu-pyrazine dibromo zinc(II))
C4H4Br2N2Zn
Journal of the Chemical Society, Dalton Transactions (2001) 8 1176
a=6.0068(4)Å b=9.9518(8)Å c=6.9936(6)Å
α=90.00° β=110.472(5)° γ=90.00°
C12H9NO2
C12H9NO2
Dalton transactions (Cambridge, England : 2003) (2012) 41, 14 4224-4231
a=10.7482(12)Å b=11.7997(13)Å c=14.7279(15)Å
α=90.00° β=90.00° γ=90.00°
C106.25H96.75Co4N11.25O23.75
C106.25H96.75Co4N11.25O23.75
Dalton transactions (Cambridge, England : 2003) (2012) 41, 14 4224-4231
a=31.9819(12)Å b=31.9819(12)Å c=25.3323(11)Å
α=90.00° β=90.00° γ=90.00°
C108.8H98.7N11.6Ni4O22.35
C108.8H98.7N11.6Ni4O22.35
Dalton transactions (Cambridge, England : 2003) (2012) 41, 14 4224-4231
a=31.8199(19)Å b=31.8199(19)Å c=25.1149(15)Å
α=90.00° β=90.00° γ=90.00°
Cis-tris-(3,3,3',3'-tetrabutyl-1,1'-terephthaloyl-bis(thiourea))platinum(II)'
C78H120N12O6Pt3S6,2(CHCl3),C2H6O,2H2O
Journal of the Chemical Society, Dalton Transactions (1999) 18 3157
a=17.611(1)Å b=23.293(2)Å c=26.033(1)Å
α=90.00° β=94.261(2)° γ=90.00°
Cis-bis-(3,3,3',3'-tetraethyl-1,1'-isophthaloyl-bis(thiourea))platinum(II)
C18H24N4O2Pt1S2
Journal of the Chemical Society, Dalton Transactions (1999) 18 3157
a=8.3986(2)Å b=9.7283(3)Å c=13.0248(4)Å
α=80.512(2)° β=82.187(3)° γ=84.719(2)°
C20H27NO18Zn2
C20H27NO18Zn2
Dalton transactions (Cambridge, England : 2003) (2010) 39, 11 2869-2874
a=7.83340(10)Å b=17.2763(4)Å c=9.4450(5)Å
α=90.00° β=100.475(2)° γ=90.00°
C52.5H72.5N5.5O41.5Zn7
C52.5H72.5N5.5O41.5Zn7
Dalton transactions (Cambridge, England : 2003) (2010) 39, 11 2869-2874
a=29.555(6)Å b=28.856(6)Å c=17.719(4)Å
α=90.00° β=90.00° γ=90.00°
Isonicotinamide
C6H6N2O1
Chem.Commun. (2011) 47, 1530
a=10.1603(7)Å b=7.3231(5)Å c=15.8720(6)Å
α=90.00° β=90.00° γ=90.00°
Nicotinamide
C6H6N2O1
Chem.Commun. (2011) 47, 1530
a=15.0634(5)Å b=10.6976(4)Å c=15.2067(5)Å
α=90.00° β=102.188(2)° γ=90.00°
C27H24N2O5Zn
C27H24N2O5Zn
CrystEngComm (2014) 16, 35 8160
a=11.6638(4)Å b=11.6638(4)Å c=36.790(3)Å
α=90° β=90° γ=90°
C24H16N2O4Zn
C24H16N2O4Zn
CrystEngComm (2014) 16, 35 8160
a=11.5806(3)Å b=11.5806(3)Å c=34.904(2)Å
α=90.00° β=90.00° γ=90.00°
C18H24N4NiO2S2
C18H24N4NiO2S2
CrystEngComm (2005) 7, 25 161
a=8.32370(10)Å b=9.61490(10)Å c=12.87170(10)Å
α=81.0900(10)° β=82.7990(10)° γ=84.6010(10)°
C198H234N36Ni6O12S12
C198H234N36Ni6O12S12
CrystEngComm (2005) 7, 25 161
a=16.4822(2)Å b=27.7131(3)Å c=22.9061(3)Å
α=90.00° β=95.7930(10)° γ=90.00°
((R)-1-phenylethylammonium).((2S)-[2-(4-isobutylphenyl)propanoate])
C13H17O2,C8H12N
CrystEngComm (2010) 12, 11 3634
a=6.8664(5)Å b=12.4548(12)Å c=23.4659(10)Å
α=90° β=90° γ=90°
((R)-1-phenylethylammonium).(2-(2-(2,6-dichlorophenylamino)phenyl)acetate)
C14H10Cl2NO2,C8H12N
CrystEngComm (2010) 12, 11 3634
a=12.499(5)Å b=6.8934(15)Å c=13.411(6)Å
α=90° β=113.73(3)° γ=90°